PRQR - Why ProQR Therapeutics Stock Got Slammed Again Monday
For the second trading day in a row, investors sold off shares of ProQR Therapeutics (NASDAQ: PRQR) . The clinical-stage biotech's shares were hit by a series of analyst downgrades and price target cuts in the wake of the company's latest report about a once-promising drug candidate. The stock closed Monday's session down by 10.1%.
On Friday, ProQR published a dispiriting update about sepofarsen , a drug candidate that it hoped would successfully treat a type of Leber congenital amaurosis, an eye disorder. In a phase 2/3 clinical trial, sepofarsen not only failed to meet its primary endpoint, it also failed to meet any notable secondary endpoints.
Image source: Getty Images.
For further details see:
Why ProQR Therapeutics Stock Got Slammed Again Monday